Kalvista stock price target raised to $27 from $19 at JMP on Ekterly pricing

Kalvista Pharmaceuticals (KALV) has received FDA approval for Ekterly, the first oral on-demand treatment for hereditary angioedema (HAE) attacks, triggering significant analyst upgrades. JMP Securities notably raised its price target to $27 and boosted Ekterly's peak sales projection to $740 million, citing the drug's $16,720 per dose pricing and unique market position. This positive outlook, shared by other firms like BofA and Stifel, has driven KALV stock up 83% over six months, reflecting strong market optimism despite noted rapid cash burn.

Analysis

Kalvista Pharmaceuticals (KALV) has received a significant positive catalyst with the FDA's approval of Ekterly, the first oral on-demand treatment for hereditary angioedema (HAE) attacks. This regulatory milestone has triggered a wave of bullish analyst sentiment, most notably from JMP Securities, which raised its price target to $27.00 and nearly doubled its peak sales projection for Ekterly to approximately $740 million. JMP's sales forecasts for fiscal years 2026 ($75M) and 2027 ($267M) are substantially higher than current consensus estimates ($32M and $119M, respectively), suggesting potential for further upward revisions across the street. The drug's market potential is framed against the historical success of Firazyr, which achieved $800 million in sales before facing generic competition in a smaller HAE market. Financially, Kalvista exhibits a strong balance sheet with more cash than debt and a current ratio of 10.44, but this is counterbalanced by a rapid cash burn that requires close monitoring during the commercial launch. The market has already reacted strongly, with the stock gaining nearly 83% over the past six months, though some signals suggest it may be trading above its intrinsic fair value, indicating high expectations are already priced in.

Key Decisions for Investors

• Given the landmark FDA approval and significantly upgraded analyst sales forecasts for Ekterly, investors may consider the stock for its long-term growth potential as the first oral on-demand HAE therapy.
• Investors should weigh the strong positive momentum against the stock's 83% gain in six months and indications of being overvalued, suggesting that much of the initial optimism may already be priced in.
• Closely monitor the company's cash burn rate and initial sales figures for Ekterly, as these will be critical indicators of successful market adoption and commercial execution against very high analyst expectations.
• Upcoming regulatory decisions in Europe and planned expansions into Japan and the UK represent key future catalysts that could further validate the bullish thesis.